Avanir is Opportunity
Unlock the future of CNS treatment
Join our team of Innovators
Avanir employees are a diverse team of dedicated, accomplished professionals united by a common purpose: striving to make a change by developing innovative treatments for central nervous system (CNS) conditions.
Addressing unmet Needs
We believe in serving patients, caretakers and prescribers by developing innovative treatments that seek to address the unmet medical needs of people with central nervous system disorders.
- Phase 1
- Phase 2
- Phase 3
- Phase 1
- Phase 2
- Phase 3
Pipeline of Ingenuity
Creating novel Treatments
Our singular focus fuels our pipeline. Through constant innovation, we continuously develop solutions for patients suffering from difficult, complicated disorders of the brain.
Science and Responsibilities
Values lead to Commitments
Commitments lead to Action
In our quest to deliver life-changing central nervous system treatments for areas of high unmet need, Avanir strives to act responsibly and ethically in everything that we do.
Committed to Research
Driven by Purpose
Our scientific excellence, knowledge of brain chemistry and function, and passion for our work enable us to deliver on our mission where others have failed or overlooked opportunity.
Always moving Forward
Stay up to Date
Access to what’s happening at Avanir now, including stories, resources and information about our products, people and company.
Tracy Ting, Avanir's Vice President of Human Resources and Chief People Officer, was featured as the executive spotlight in a recent article written by American Healthcare Leader (AHL).
Tracy Ting, Avanir's Vice President of Human Resources and Chief People Officer, was featured as the executive spotlight in a recent article written by American Healthcare Leader (AHL). The article highlights Ting's work and dedication to Avanir's mission, vision and values. It also
-- Partnership Includes Series of Caregiver Lunch & Learn Workshops and Caregiver Care Packages in Select Markets -- ALISO VIEJO, Calif. and WASHINGTON, D.C. – July 18, 2018 – Avanir Pharmaceuticals, Inc. and Caregiver Action Network (CAN) today announced a partnership to provide caregivers
Avanir pharmaceuticals today launched a national, multi-channel campaign aimed at raising awareness of Pseudobulbar Affect, an often ignored and under treated neurologic condition that occurs secondary to certain neurologic injury or disease. According to a large Harris Poll online survey,
Avanir Pharmaceuticals, Inc. an indirect subsidiary of Otsuka Holdings Co., Ltd., announced Friday, January 19, that the latter has signed the CEO Statement of Support for the Women’s Empowerment Principles (WEPs), a set of Principles focusing on corporate action to promote gender
According to a new report, the amount of American lives altered by Alzheimer’s disease (AD) continues to grow. Researchers discovered that roughly 5+ million Americans had Alzheimer’s or mild cognitive impairment (MCI) as a result of the disease in 2017. The report also revealed that 16 million
We vehemently oppose any mischaracterization of how Avanir and other members of the pharmaceutical industry interact with the medical community, including physicians that educate other health care professionals about medicines. Patients and doctors want options for treatment and
We stand proudly by our commitment to research and development of treatments for CNS disorders and our relationships with advocacy organizations in our overarching commitment to help and support these patients and care communities. Our donations and support assist these organizations in
PBA is a neurological condition that affects up to an estimated 2 million Americans, but can be misunderstood by patients and their families. When someone with PBA has an intense laughing or crying episode, he or she can feel powerless, embarrassed, or discomforted. PBA occurs in people who already
In this interview with Modern Counsel magazine, Avanir VP and General Counsel Garlan Adams shares her thoughts on how the biotechnology and pharmaceutical industry is transforming disease treatment. Based on her 18 years of industry experience, Garlan describes the challenges of the drug